Article

Alcon launches Web site for patients with nasal allergies

Alcon Laboratories Inc. announced in a prepared statement the launch of a new online resource for patients with nasal allergies: its new Web site for olopatadine (Patanase) nasal spray, www.patanese.com.

Fort Worth, TX

―Alcon Laboratories Inc. announced in a prepared statement the launch of a new online resource for patients with nasal allergies: its new Web site for olopatadine (Patanase) nasal spray,

www.patanase.com

.

The site features facts about the causes of seasonal allergies, an interactive symptoms poll, complete product prescribing information and instructions, and a mail-in rebate for patients.

“This Web site is a great resource since more patients are doing online research to learn about their allergies,” said Bobby Lanier, MD, clinical professor at the University of North Texas Health Science Center, Fort Worth. “It addresses the important need for patients to understand their symptoms and how to get quick, safe relief.”

Olopatadine is a steroid-free nasal spray indicated for the relief of the symptoms of seasonal allergic rhinitis in patients aged 12 or more years.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.